Biomanufacturing and xenotransplantation technologies are transitioning from experimental stages to clinical reality to address the global solid-organ shortage. For tech professionals, this shift necessitates the development of reproducible, GMP-grade biofabrication processes and sophisticated bioprocessing pipelines capable of managing complex vascularization and structural hierarchy at scale. Success in this sector will transform transplantation into a standardized, industrialized therapy where life-saving organs are manufactured as products rather than harvested from scarce donors.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.





